PHILADELPHIA — GlaxoSmithKline’s Flonase may not be on today’s top five bestselling cough-cold-allergy-sinus products list, but it won’t be long until the brand breaks through. In the first four months on shelf, Flonase generated more than $139 million in sales, and that doesn’t include half of the summer allergy season, the fall allergy season or the cough-cold season.
The real question is how close will Flonase get to unseating Zyrtec as market leader? If sales continue at the current pace, it could exceed annual Zyrtec sales by more than $100 million.
(Click here for the full Category Review.)